PMGC Holdings Amends Executive Consulting Agreements, Setting Annual Fees at $660,000
ELAB is trading near its 52-week low of $3.38 (12% above the low) on light trading volume (0.2× avg).
Summary
PMGC Holdings Inc. has amended consulting agreements for its CEO/CFO/Director and Non-Executive Chairman, establishing combined annual fees of $660,000, effective January 1, 2026.
Key Events · Executive and Board Changes · ELAB
-
CEO/CFO/Director Compensation Set
The annual consulting fee for Graydon Bensler, serving as CEO, CFO, and Director via GB Capital Ltd, has been set at $300,000.
-
Chairman Compensation Set
The annual consulting fee for Braeden Lichti, serving as Non-Executive Chairman via Northstrive Companies Inc., has been set at $360,000.
-
Agreements Effective January 1, 2026
Both amended consulting agreements are effective as of January 1, 2026, establishing these annual fees for the current fiscal year.
-
Fifth Amendment to Existing Agreements
These are the fifth amendments to consulting agreements originally established on October 25, 2024, indicating ongoing adjustments to executive compensation.
Analysis · ELAB · Life Sciences
For a company with a market capitalization of approximately $1.9 million, annual executive consulting fees totaling $660,000 represent a substantial fixed cost. This level of compensation is a very significant portion of the company's current valuation, raising significant concerns about cash burn and the allocation of resources, potentially impacting the company's financial runway and investor confidence.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $3.38 to $686.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.